HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01 Changes in Registrant’s Certifying Accountant.

On April 2, 2018, the Company released RSM US LLP (“RSM”) as its independent registered public accounting firm. The decision to rotate the independent registered public accounting firms was approved by the Audit Committee of the Company’s Board of Directors (the “Audit Committee”). The Audit Committee determined to transition to another accounting firm for best practices as RSM had been the Company’s auditors for 12 years. In this regard, on April 4, 2018, the Audit Committee entered into an agreement with Morrison, Brown, Argiz & Farra, LLC (“MBAF”) to serve as the Company’s independent registered public accounting firm. The Company did not consult with MBAF regarding any of the matters or events set forth in Item 304(a)(2)(ii) of Regulation S-K.

During the Company’s two most recent fiscal years and from January 1, 2018 through the date hereof, there were (i) no disagreements between the Company and RSM on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreement, if not resolved to the satisfaction of RSM, would have caused RSM to make reference thereto in their reports on the financial statements for such years, and (ii) no “reportable events” as that term is defined in Item 304(a)(1)(v) of Regulation S-K, except as follows. As noted in the Company’s quarterly reports on Form 10-Q for the second and third quarters of 2017, the Company, in carrying out an evaluation of the effectiveness of its disclosure controls and procedures, determined that, at the end of these quarters, there was a material weakness. The material weakness related to the completeness and accuracy of the recording of the exercise of certain redeemable warrants. The Company’s audit committee discussed this material weakness with RSM during the second and third quarters of 2017. The Company has authorized RSM to respond fully to the inquiries of MBAF regarding the previously reported material weakness. The Company believes that it has corrected this issue and no such material weakness was found during the fourth quarter of 2017.

The reports of RSM for the fiscal years ended December 31, 2017 and December 31, 2016 contained no adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

The Company provided RSM and MBAF with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (“SEC”) and requested that RSM furnish it with a letter addressed to the SEC stating whether or not it agrees with the above statements in this Item 4.01 and if not, stating the respects in which it does not agree. A copy of RSM’s letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

HEMISPHERX BIOPHARMA INC Exhibit
…
To view the full exhibit click here

About HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company’s products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.

HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB) Recent Trading Information

HEMISPHERX BIOPHARMA, INC. (NYSEAMERICAN:HEB) closed its last trading session down -0.005 at 0.425 with shares trading hands.